Jan Stahlberg Purchases 182,882 Shares of DiaMedica Therapeutics (NASDAQ:DMAC) Stock

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) major shareholder Jan Stahlberg bought 182,882 shares of the stock in a transaction on Tuesday, November 18th. The stock was purchased at an average cost of $6.75 per share, with a total value of $1,234,453.50. Following the acquisition, the insider owned 8,134,740 shares in the company, valued at approximately $54,909,495. This represents a 2.30% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Jan Stahlberg also recently made the following trade(s):

• On Tuesday, November 25th, Jan Stahlberg bought 73,099 shares of DiaMedica Therapeutics stock. The stock was purchased at an average price of $8.57 per share, with a total value of $626,458.43.
• On Monday, November 24th, Jan Stahlberg purchased 40,253 shares of DiaMedica Therapeutics stock. The shares were purchased at an average cost of $7.89 per share, for a total transaction of $317,596.17.
• On Friday, November 21st, Jan Stahlberg purchased 208,872 shares of DiaMedica Therapeutics stock. The shares were purchased at an average price of $7.41 per share, for a total transaction of $1,547,741.52.
• On Thursday, November 20th, Jan Stahlberg acquired 128,426 shares of DiaMedica Therapeutics stock. The stock was acquired at an average price of $7.41 per share, with a total value of $951,636.66.
• On Wednesday, November 19th, Jan Stahlberg bought 240,352 shares of DiaMedica Therapeutics stock. The shares were acquired at an average price of $7.21 per share, for a total transaction of $1,732,937.92.
• On Monday, November 17th, Jan Stahlberg bought 187,393 shares of DiaMedica Therapeutics stock. The shares were acquired at an average cost of $6.52 per share, for a total transaction of $1,221,802.36.

DiaMedica Therapeutics Stock Performance

Shares of NASDAQ DMAC opened at $9.07 on Wednesday. The firm has a 50 day moving average price of $7.20 and a two-hundred day moving average price of $5.76. The stock has a market cap of $472.37 million, a P/E ratio of -12.77 and a beta of 1.31. DiaMedica Therapeutics, Inc. has a 52-week low of $3.19 and a 52-week high of $9.35.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Analysts predict that DiaMedica Therapeutics, Inc. will post -0.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on DMAC shares. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Wednesday, October 8th. TD Cowen assumed coverage on shares of DiaMedica Therapeutics in a report on Thursday, October 30th. They set a “buy” rating for the company. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of DiaMedica Therapeutics in a research note on Friday, August 15th. Wall Street Zen cut shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Finally, Cantor Fitzgerald initiated coverage on shares of DiaMedica Therapeutics in a report on Friday, November 14th. They issued an “overweight” rating on the stock. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.33.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. acquired a new position in shares of DiaMedica Therapeutics during the third quarter valued at about $27,000. Police & Firemen s Retirement System of New Jersey bought a new stake in DiaMedica Therapeutics in the 2nd quarter valued at about $29,000. Bank of America Corp DE boosted its holdings in DiaMedica Therapeutics by 3,710.3% in the second quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock worth $33,000 after acquiring an additional 8,274 shares in the last quarter. Strs Ohio boosted its holdings in DiaMedica Therapeutics by 19.7% in the third quarter. Strs Ohio now owns 9,100 shares of the company’s stock worth $63,000 after acquiring an additional 1,500 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in DiaMedica Therapeutics in the second quarter valued at approximately $49,000. 10.12% of the stock is currently owned by institutional investors and hedge funds.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.